Mother's and Kyungdong Pharmaceutical won the patent dispute over DPP-4 Inhibitor Series Diabetes Complex Tenelia M SR (Metformin HCl + Teneligliptin Hydrobromide Hydrate).

This is expected to compete with Genuonescience, which won ahead of the two companies with the early release of generic for Tenelia M SR.

According to the pharmaceutical industry on the 22nd, the Intellectual Property Trial and Appeal Board decided on the 21st at the Defensive Confirmation Trial for the Scope of a Right, which Mother's and Kyung Dong filed against Korea.

The patent applied to Tenelia M SR is a formulation patent that expires in 2034. In January this year, Genuonescience filed a trial a